Results 131 to 140 of about 110,078 (271)
The AMR footprint: an integrative indicator in the global response to antimicrobial resistance. [PDF]
Essack SY.
europepmc +1 more source
null 유장순 +3 more
openaire +1 more source
Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla +10 more
wiley +1 more source
crRNA scaffold remodeling controls CRISPR-Cas12a activity for enhanced performance. [PDF]
Wang Z +11 more
europepmc +1 more source
Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li +10 more
wiley +1 more source
Disruption of <i>TcGNBP3</i> via RNA interference compromises antibacterial immunity in <i>Tribolium castaneum</i>. [PDF]
Bi J +9 more
europepmc +1 more source
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala +15 more
wiley +1 more source
Potential of Vγ9Vδ2T cells in tuberculosis: integration of innate and adaptive immunity for vaccine development. [PDF]
Di D, Gao C, Deng Y, Li Y, Zhang Y.
europepmc +1 more source
Tetuyuki SASAKI, Kazutaka KUROSAWA
openaire +2 more sources

